Major shareholder completes stake reduction in Pharmaron Beijing

Shenzhen Zhongjia Kangcheng Investment Partnership, a shareholder holding over 5% of Pharmaron Beijing Co., Ltd., has completed its share reduction plan. The plan, disclosed on May 16, 2025, and starting on June 10, 2025, involved reducing its stake by up to 26,672,932 shares, representing 1.50% of the company's total share capital.

The reduction was executed through a combination of block trading and centralized bidding. Zhongjia Kangcheng reduced 9,068,861 shares via block trading between July 2025 and September 2025 at an average price of CNY29.61 per share, accounting for 0.51% of total shares. Additionally, 17,604,071 shares were sold via centralized bidding between June 2025 and September 2025 at an average price of CNY25.57 per share, representing 0.99% of total shares. The total shares reduced amounted to 26,672,932, achieving the full 1.50% target.

Following the completion of the reduction, Zhongjia Kangcheng and its concert party, Shenzhen Zhongjia Longcheng Investment Partnership, now collectively hold 14.17% of Pharmaron Beijing's shares, down from 15.67%. The company confirmed that the reduction was conducted in compliance with relevant regulations and will not alter the company's control or negatively impact its governance or ongoing operations.